Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

Published:2015-02 Issue: Volume:57 Page:60-65
ISSN:0896-8411
Container-title:Journal of Autoimmunity
language:en
Short-container-title:Journal of Autoimmunity

Author:

Roberts Darren M.^ORCID,Jones Rachel B.,Smith Rona M.,Alberici Federico,Kumaratne Dinakantha S.^ORCID,Burns Stella,Jayne David R.W.

Funder

Cambridge Biomedical Research Centre

University of Cambridge, Royal Australasian College of Physicians and Amgen (Australia)

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference43 articles.

1. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum,2006

2. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis;Edwards;N Engl J Med,2004

3. Rituximab versus cyclophosphamide for ANCA-associated vasculitis;Stone;N Engl J Med,2010

4. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis;Jones;N Engl J Med,2010

5. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis;Smith;Arthritis Rheum,2012

Cited by 245 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience;Journal of Clinical Immunology;2024-08-16

2. Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy;Cancer Medicine;2024-08

3. The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis;Doklady Biochemistry and Biophysics;2024-06-10

4. Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis;Doklady Biochemistry and Biophysics;2024-06-10

5. Disseminated septic arthritis caused by Ureaplasma urealyticum in an immunocompromised patient with hypogammaglobulinemia after rituximab therapy;Infection;2024-06-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3